

List of Tables

Table No.	Table Captions	Page No.
4.1.	Effect of process variables on particle size of placebo nanoparticles	55
4.2.	Factorial design parameters and experimental conditions	56
4.3.	Formulations of the nanoparticles using 3 ² factorial design	56
4.4.	List of excipients and quantities used in preparation of naplet	59
4.5.	Composition of different batches of naplets	59
4.6.	Excipients and quantities used for sub and enteric coating of naplets	60
4.7.	Animal groups used in pharmacokinetic study	70
4.8.	Animal groups used in toxicity study	75
5.1.	HPLC analytical method validation parameters	77
5.2.	Solubility studies of BBR in different media	81
5.3.	Solubility studies of BBR in different surfactants in pH 4.5 buffer	82
5.4.	Effect of Injection rate, needle size and stirring rate on particle size of placebo nanoparticles	84
5.5.	Results of EE, PS and PDI of formulations F1 – F9	86
5.6.	Results of PS, PDI, ZP and EE of BBR-NP	93

	and BBR-SCNP	
5.7.	Results of redispersion, hardness, friability and disintegration of different naplet batches	97
5.8.	PS, PDI and ZP of BBR-NP dispersion and redispersed nanoparticles of naplet	98
5.9.	Stability studies of BBR-NP formulation (F-6)	112
5.10.	Stability studies of BBR-SCNP formulation	112
5.11.	Stability studies of naplet	114
5.12.	Results of BBR-NP and BBR-SCNP after 30 min of incubation in SBFs at different pHs	119
5.13.	HPLC bio analytical method validation parameters	120
5.14.	Pharmacokinetic parameters of different animal groups	123
5.15.	Liver and Kidney enzymes normal values	133